The increasing trend of highly potent active pharmaceutical ingredients (HPAPIs) being used in new drug development candidates has created a tremendous demand for high containment development and production capabilities. Learn more about Alcami's HPAPI capabilities.
WILMINGTON, N.C., August 26, 2020 - Alcami, a US-based CDMO, announced today that it is providing commercial services for Trevena’s newly approved OLINVYK. OLINVYK (oliceridine) injection is an opioid approved in adults for the management of acute pain severe enough to require an intravenous opioid analgesic. Alcami has provided development and clinical support for this program for several years leading up to Trevena’s approval from the U.S. Food and Drug Administration.
MORRISVILLE, N.C., July 28, 2020 -- Alcami, a US-based CDMO, is pleased to announce that its 56,000 square foot expansion in Research Triangle Park (RTP), reached the first milestone of operational readiness with the start of GMP laboratory testing this month. 20,000 square feet will be dedicated to microbiology, formulation development, and analytical chemistry services. Specific investment has been made to offer industry-leading environmental monitoring services from this site in 2020.